Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRUKER CORPBRKR · Entity 3609 | Director | February 15, 2026 | February 18, 2026 |
| SI-BONE, Inc.SIBN · Entity 2501 | Director · Chief Executive Officer | October 12, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRUKER CORP
Report date February 15, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,018 |
Reported balance
After 2026-02-15 transaction · row 1
1 source rowRow 1 · 2026-02-15 · Grant · Acquired 4,520 · Balance 9,018 F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock.
SI-BONE, Inc.
Report date October 12, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 379,256 |
Reported balance
After 2026-10-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 38,006 · Balance 379,256 F1: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated May 21, 2026. F2: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.1050, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3: Reflects the transfer of shares from the Reporting Person to The David & Laura Joint Rev Tr. F4: Shares held by The David & Laura Joint Rev Tr. |
| Common StockSEC Table I · non-derivative | Direct | 368,129 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 368,129 F5: Includes 355,697 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated May 21, 2026.
F2: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.1050, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
F3: Reflects the transfer of shares from the Reporting Person to The David & Laura Joint Rev Tr.
F4: Shares held by The David & Laura Joint Rev Tr.
F5: Includes 355,697 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Shockwave Medical, Inc.
Report date May 31, 2024 · Filed May 31, 2024
Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Disposition to issuer · Disposed 1,233 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectDavid and Laura Francis Joint Rev Trust | 0 |
Reported balance
After 2024-05-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-05-31 · Disposition to issuer · Disposed 3,551 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. F3: These shares are held in a trust for the benefit of the reporting person's children. The reporting person and the reporting person's spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.59 · Expires 2029-02-01 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-31 · Disposition to issuer · Disposed 13,690 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),
F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
F3: These shares are held in a trust for the benefit of the reporting person's children. The reporting person and the reporting person's spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2023 Filed Aug 24, 2023 00:07 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 497 | $220.97 | $109,822.09 |
DisclosureSEC source: 0001209191-23-047136 · doc4.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Plan reported Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 3,054 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/23/2023. F2 · price: All reported securities were sold at a price of $220.97. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,181 | $20.96 | $45,718.12 |
DisclosureSEC source: 0001562180-23-006435 · primarydocument.xml · nonDerivative · entry 6 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,039 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $20.78 USD to $21.17 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · balance_after: Includes 252,139 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,982 | $20.94 | $41,507.64 |
DisclosureSEC source: 0001562180-23-006435 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 439,220 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $20.78 USD to $21.16 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,020 | $20.94 | $21,362.06 |
DisclosureSEC source: 0001562180-23-006435 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,202 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.78 USD to $21.18 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,678 | $20.95 | $35,147.39 |
DisclosureSEC source: 0001562180-23-006435 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 442,222 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.775 USD to $21.18 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,530 | $20.97 | $32,084.10 |
DisclosureSEC source: 0001562180-23-006435 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,900 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.78 USD to $21.18 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 621 | $21.06 | $13,080.50 |
DisclosureSEC source: 0001562180-23-006435 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 445,430 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.02 USD to $21.10 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:48 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 736 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037554 · doc4.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,730 Read SEC document |
| May 16, 2023 Filed May 18, 2023 21:36 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,677 | $24.85 | $41,666.41 |
DisclosureSEC source: 0001562180-23-004251 · primarydocument.xml · nonDerivative · entry 6 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,051 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $24.37 USD to $24.99 USD; the price reported above reflects the weighted average sale price.The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · balance_after: Includes 1,892 shares acquired under the SI-BONE, Inc. 2018 Employee Stock Purchase Plan on May 15, 2023. F8 · balance_after: Includes 270,283 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 16, 2023 Filed May 18, 2023 21:36 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 621 | $24.73 | $15,355.09 |
DisclosureSEC source: 0001562180-23-004251 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 445,836 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $24.37 USD to $24.85 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2023 Filed May 18, 2023 21:36 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,020 | $24.84 | $25,333.84 |
DisclosureSEC source: 0001562180-23-004251 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,457 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $24.34 USD to $24.96 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2023 Filed May 18, 2023 21:36 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,529 | $24.85 | $37,990.91 |
DisclosureSEC source: 0001562180-23-004251 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 447,477 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $24.37 USD to $24.99 USD; the price reported above reflects the weighted average sale price.The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2023 Filed May 18, 2023 21:36 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,180 | $24.85 | $54,178.89 |
DisclosureSEC source: 0001562180-23-004251 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,006 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $24.34 USD to $24.95 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2023 Filed May 18, 2023 21:36 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,982 | $24.85 | $49,253.69 |
DisclosureSEC source: 0001562180-23-004251 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,186 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.34 USD to $24.99 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 23:45 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GiftStock Options (Right to buy) · Derivative | 9,863 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002189 · primarydocument.xml · derivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,574 Underlying: Common Stock · 9,863 shares Expires 2029-01-15 F5 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date. F6 · balance_after: The reported transaction involves the Reporting Person's transfer of options to trusts for the benefit of Reporting Person's children. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 23:45 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-23-002189 · primarydocument.xml · derivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,392 Underlying: Common Stock · 35,000 shares Expires 2025-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on May 26, 2015, subject to Reporting Person's continued service through each relevant vesting date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 23:45 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 35,000 | $20.23 | $708,172.50 |
DisclosureSEC source: 0001562180-23-002189 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,168 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.90, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 288,428 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer'scommon stock. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 23:45 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionCommon Stock | 35,000 | $4.32 | $151,200.00 |
DisclosureSEC source: 0001562180-23-002189 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:08 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 7,170 | $16.78 | $120,344.87 |
DisclosureSEC source: 0001562180-23-001496 · primarydocument.xml · nonDerivative · entry 7 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,168 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 288,428 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:08 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 613 | $16.81 | $10,302.02 |
DisclosureSEC source: 0001562180-23-001496 · primarydocument.xml · nonDerivative · entry 6 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,338 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:08 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 698 | $16.82 | $11,740.50 |
DisclosureSEC source: 0001562180-23-001496 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,951 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:08 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,155 | $16.82 | $19,426.41 |
DisclosureSEC source: 0001562180-23-001496 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,649 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:08 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,007 | $16.74 | $16,858.89 |
DisclosureSEC source: 0001562180-23-001496 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,804 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:08 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,476 | $16.71 | $24,662.34 |
DisclosureSEC source: 0001562180-23-001496 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,811 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:08 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,364 | $16.75 | $22,850.00 |
DisclosureSEC source: 0001562180-23-001496 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,287 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 23:50 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 70,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000313 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,651 F2 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest, if at all, over three years based on the Issuer's total shareholder return (TSR) as measured against the TSR of the company at the median of the range TSRs of a set of peer companies established by the Issuer as set forth in the grant. F3 · balance_after: Includes 324,894 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 23:50 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 70,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000313 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,399 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest over four years beginning on April 1, 2023, and will be released in quarterly installments, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:33 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,383 | $17.29 | $23,908.20 |
DisclosureSEC source: 0001562180-22-006195 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,147 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 205,794 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:33 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,067 | $17.29 | $18,445.44 |
DisclosureSEC source: 0001562180-22-006195 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,530 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:33 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,006 | $17.29 | $17,390.92 |
DisclosureSEC source: 0001562180-22-006195 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,597 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:33 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,171 | $17.29 | $20,243.31 |
DisclosureSEC source: 0001562180-22-006195 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,603 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:33 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 621 | $17.29 | $10,735.35 |
DisclosureSEC source: 0001562180-22-006195 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,774 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 27, 2022 Filed Feb 15, 2023 02:02 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009583 · doc5.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 994 F1 · shares: On June 27, 2022, the reporting person transferred 850 shares of the issuer's common stock to a family trust of which the reporting person is trustee. The reporting person and members of her immediate family are the sole beneficiaries of the trust. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 23:54 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039541 · doc4.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,844 Read SEC document |
| May 16, 2022 Filed May 18, 2022 00:54 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 712 | $12.58 | $8,957.46 |
DisclosureSEC source: 0001562180-22-004166 · primarydocument.xml · nonDerivative · entry 6 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,395 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 219,547 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: Includes 1,134 shares acquired under the SI-BONE, Inc. 2018 Employee Stock Purchase Plan on May 15, 2022. Read SEC document |
| May 16, 2022 Filed May 18, 2022 00:54 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 434 | $12.58 | $5,460.02 |
DisclosureSEC source: 0001562180-22-004166 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,973 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 16, 2022 Filed May 18, 2022 00:54 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,172 | $12.58 | $14,744.58 |
DisclosureSEC source: 0001562180-22-004166 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,407 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 16, 2022 Filed May 18, 2022 00:54 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,384 | $12.58 | $17,411.69 |
DisclosureSEC source: 0001562180-22-004166 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,579 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 16, 2022 Filed May 18, 2022 00:54 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,068 | $12.58 | $13,436.19 |
DisclosureSEC source: 0001562180-22-004166 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,963 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 16, 2022 Filed May 18, 2022 00:54 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 35 | $12.58 | $440.32 |
DisclosureSEC source: 0001562180-22-004166 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,031 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,890 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · derivative · entry 17 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,190 Underlying: Common Stock · 1,890 shares Expires 2029-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. F13 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly from 1/3/19. Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,890 | $210.00 | $396,900.00 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 15 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 0 F12 · price: All reported securities were sold at a price of $210.00. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 1,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 14 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 1,890 F2 · kind: Represents a bona fide gift of securities by the reporting person to the David and Laura Francis Joint Revocable Trust in an exempt transaction pursuant to Rule 16b-5. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 1,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 13 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,551 F2 · kind: Represents a bona fide gift of securities by the reporting person to the David and Laura Francis Joint Revocable Trust in an exempt transaction pursuant to Rule 16b-5. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,890 | $6.59 | $12,455.10 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 12 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 2,310 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · derivative · entry 16 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,080 Underlying: Common Stock · 2,310 shares Expires 2029-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. F13 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly from 1/3/19. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 22 | $198.84 | $4,374.48 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 11 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 0 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. F11 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $198.79 to $199.13. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 120 | $198.14 | $23,776.80 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 10 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 22 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. F10 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $197.72 to $198.52. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 300 | $197.20 | $59,160.00 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 9 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 142 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. F9 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $196.63 to $197.60. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 769 | $195.91 | $150,654.79 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 8 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 442 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. F8 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $195.50 to $196.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.